CytomX Therapeutics

CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probodies are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody™ approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets.